Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...
Eli Lilly and Company has invested more than $20 billion in its manufacturing capabilities since 2020 to help meet high ...
Eli Lilly and Company (NYSE: LLY) will attend the 43rd Annual J.P. Morgan Healthcare Conference, Jan. 13-16, 2025. David A.
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price ...
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
LY-4052031 is under clinical development by Eli Lilly and Co and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...
LY-4101174 is under clinical development by Eli Lilly and Co and currently in Phase I for Non-Small Cell Lung Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback